Payment overview · 2025
General Payments
$14.89
1 reported records · 1 companies
Healthcare provider profile · identity verified
Christopher Marks Leach, MD
Allopathic & Osteopathic Physicians|Family Medicine · O'DONNELL, TX · NPI 1881040665
Verified facts
What the public records show
CMS Open Payments records show Christopher Marks Leach, MD received $14.89 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.89 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.89 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 544 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 353 | 73 |
| Gabapentin | Gabapentin | 349 | 89 |
| Lisinopril | Lisinopril | 320 | 64 |
| Potassium Chloride | Potassium Chloride | 313 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 54 |
| Furosemide | Furosemide | 256 | 55 |
| Meloxicam | Meloxicam | 221 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 58 |
| Eliquis | Apixaban | 185 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 39 |
| Losartan Potassium | Losartan Potassium | 167 | 37 |
| Sertraline Hcl | Sertraline Hcl | 155 | 20 |
| Metformin Hcl | Metformin Hcl | 153 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 37 |
| Tramadol Hcl | Tramadol Hcl | 137 | 41 |
| Divalproex Sodium | Divalproex Sodium | 135 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 18 |
| Montelukast Sodium | Montelukast Sodium | 112 | 32 |
| Azithromycin | Azithromycin | 104 | 88 |
| Trazodone Hcl | Trazodone Hcl | 103 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 21 |
| Buspirone Hcl | Buspirone Hcl | 99 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 16 |
| Donepezil Hcl | Donepezil Hcl | 88 | 16 |
| Alprazolam | Alprazolam | 83 | 16 |
| Levetiracetam | Levetiracetam | 79 | suppressed |
| Cephalexin | Cephalexin | 76 | 60 |
| Januvia | Sitagliptin Phosphate | 76 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 17 |
| Simvastatin | Simvastatin | 75 | 14 |
| Sodium Chloride | 0.9 % Sodium Chloride | 75 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 41 |
| Jardiance | Empagliflozin | 73 | 11 |
| Glipizide | Glipizide | 72 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 25 |
| Prednisone | Prednisone | 72 | 38 |
| Carvedilol | Carvedilol | 71 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 21 |
| Pregabalin | Pregabalin | 67 | 12 |
| Atenolol | Atenolol | 66 | 16 |
| Omeprazole | Omeprazole | 65 | 16 |
| Enulose | Lactulose | 64 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 14 |
| Allopurinol | Allopurinol | 61 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 12 |
| Mounjaro | Tirzepatide | 59 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 25 |
| Metoclopramide Hcl | Metoclopramide Hcl | 58 | suppressed |
| Myrbetriq | Mirabegron | 58 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 38 |
| Mirtazapine | Mirtazapine | 53 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 41 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 11 |
| Carbamazepine | Carbamazepine | 45 | suppressed |
| Latanoprost | Latanoprost | 45 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 30 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 40 | 34 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Brilinta | Ticagrelor | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | 12 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 35 | suppressed |
| Olanzapine | Olanzapine | 35 | 11 |
| Phenobarbital | Phenobarbital | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 11 |
| Ozempic | Semaglutide | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 28 | 28 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 17 |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Austedo | Deutetrabenazine | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Ondansetron Odt | Ondansetron | 20 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 18 | 14 |
| Famotidine | Famotidine | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lactulose | Lactulose | 17 | 13 |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.89 · 1 records | Novo Nordisk Inc | — | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error